Study Evaluating Venlafaxine ER in Adults With Panic Disorder

Wyeth is now a wholly owned subsidiary of Pfizer343 enrolled

Overview

The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

343

Conditions

Panic Disorder

Interventions

Venlafaxine ERDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A male or female outpatient * Be at least 18 years of age and legal age of consent * Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1 Exclusion Criteria: * Treatment with venlafaxine (IR or ER) within 6 months of study day 1 * Known hypersensitivity to venlafaxine (IR or ER) or related compounds * History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.